MarketPeel
Insider Trading Intelligence
Pricing
…
JH

James Healy

BIOA
DIRECTOR · BIOAGE LABS, INC. · CIK 0001245624
FILING MIX · LIFETIME78%/22%
BUYS
80
SELLS
22
TOTAL VALUE
$100.70M
COMPANIES
8
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
6,078,438
AVG SELL PX
$29.09
TRADE KIND
SHOWING 102 / 102
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
33 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by James Healy, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d33+33.33%-1.49%+1.27%-2.77%-5.23%-2.58
14d33+33.33%-1.02%+1.54%-2.57%-4.70%-1.60
30d33+33.33%-3.22%+1.78%-5.00%-11.70%-1.93
60d33+12.12%-10.93%+3.29%-14.22%-17.87%-5.35
90d33+12.12%-23.81%+5.33%-29.13%-25.03%-5.95
180d33+21.21%-23.46%+8.53%-31.99%-35.01%-4.03
1y33+21.21%-25.96%+13.17%-39.13%-69.87%-2.39
2y33(5 pending)+89.29%+59.40%+33.17%+26.23%+26.86%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BIOA · 22,000 shares · as of Jun 10, 2026
0556,7811,113,5621,670,3432,227,12420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 80 buys / 22 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,200——15,200Jun 10, 2026Jun 10, 2026 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASEGRANT
Stock grant
22,000——22,000Jun 10, 2026Jun 12, 2026 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,850——21,850Jun 17, 2025Jun 18, 2025 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASEGRANT
Stock grant
22,000——22,000Jun 5, 2025Jun 9, 2025 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
142——46,260Apr 25, 2025Apr 29, 2025 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
114——46,118Jan 31, 2025Feb 4, 2025 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
153——46,004Oct 25, 2024Oct 29, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
588,888$18.00$10.60M2,227,124Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
1,638,236——1,638,236Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
26,497$18.00$476.9K26,497Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
21,814$18.00$392.7K21,814Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
SALE
7,310,796——0Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
18,353$18.00$330.4K18,353Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
11,113$18.00$200.0K11,113Sep 27, 2024Sep 27, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Sep 25, 2024Sep 27, 2024 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
177——45,851Jul 26, 2024Jul 30, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,799$23.08$87.7K21,660Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,828$24.21$92.7K25,488Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,538$23.08$81.6K28,993Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,630$23.08$83.8K29,908Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,657$24.21$88.5K33,565Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
4,661$25.02$116.6K38,226Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
4,878$25.02$122.0K30,366Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
4,544$25.02$113.7K37,102Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
2,559$26.06$66.7K39,661Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,565$24.21$86.3K32,558Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
2,748$26.06$71.6K33,114Jul 1, 2024Jul 3, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
2,625$26.06$68.4K40,851Jul 1, 2024Jul 3, 2024 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
2,964——45,674Jun 28, 2024Jul 2, 2024 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
22,000——22,000Jun 12, 2024Jun 14, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE
11,924,138——0Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
1,392,738——1,392,738Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
470,589$17.00$8.00M1,863,327Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
17,861$17.00$303.6K17,861Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
26,278$17.00$446.7K26,278Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
25,455$17.00$432.7K25,455Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
18,641$17.00$316.9K18,641Jun 10, 2024Jun 10, 2024 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
210——42,710Apr 26, 2024Apr 30, 2024 ↗View →
AVBP
ARRIVENT BIOPHARMA, INC.
PURCHASE
444,444$18.00$8.00M1,696,752Jan 30, 2024Jan 31, 2024 ↗View →
AVBP
ARRIVENT BIOPHARMA, INC.
SALE
1,252,308——0Jan 30, 2024Jan 31, 2024 ↗View →
AVBP
ARRIVENT BIOPHARMA, INC.
PURCHASE
1,252,308——1,252,308Jan 30, 2024Jan 31, 2024 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
264$63.79$16.8K42,500Jan 26, 2024Jan 30, 2024 ↗View →
NTRA
NATERA, INC.
SALE
644,000$58.75$37.84M0Dec 13, 2023Dec 21, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
396$42.60$16.9K42,236Oct 27, 2023Oct 31, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
328$48.48$15.9K41,840Jul 28, 2023Aug 1, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
4,255——4,255Jun 30, 2023Jul 5, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
2,750——41,512Jun 30, 2023Jul 5, 2023 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 12, 2023Jun 14, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASE
3,534——38,762May 25, 2023May 30, 2023 ↗View →
NTRA
NATERA, INC.
SALE
3,534——0May 25, 2023May 30, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
285$54.73$15.6K35,228Apr 14, 2023Apr 18, 2023 ↗View →
VERA
VERA THERAPEUTICS, INC.
PURCHASE
285,714$7.00$2.00M3,467,156Feb 6, 2023Feb 8, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
390$40.01$15.6K34,943Jan 13, 2023Jan 18, 2023 ↗View →
NTRA
NATERA, INC.
SALE
2,400$37.71$90.5K0Nov 16, 2022Jan 17, 2023 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
344$45.42$15.6K34,553Oct 14, 2022Oct 18, 2022 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
430$36.31$15.6K430Jul 8, 2022Jul 12, 2022 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
430——34,209Jul 8, 2022Sep 2, 2022 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 10, 2022Jun 10, 2022 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
3,534——3,534May 27, 2022Jun 1, 2022 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
7,068——7,068May 27, 2022Jun 1, 2022 ↗View →
NTRA
NATERA, INC.
SALE
1,307——0May 25, 2022May 27, 2022 ↗View →
NTRA
NATERA, INC.
PURCHASE
1,307——33,779May 25, 2022May 27, 2022 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Mar 24, 2022Mar 28, 2022 ↗View →
VERA
VERA THERAPEUTICS, INC.
PURCHASE
266,666$15.00$4.00M3,181,442Feb 10, 2022Feb 11, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
27,000——27,000Jan 7, 2022Jan 7, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
27,000——27,000Jan 7, 2022Feb 11, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
286,076$16.12$4.61M0Sep 29, 2021Sep 29, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
48,329$17.17$829.8K286,076Sep 28, 2021Sep 29, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
100,150$18.06$1.81M334,405Sep 27, 2021Sep 29, 2021 ↗View →
NTRA
NATERA, INC.
PURCHASE
2,400$113.00$271.2K2,400Jul 22, 2021Jul 26, 2021 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
2,614——2,614May 28, 2021Jun 2, 2021 ↗View →
NTRA
NATERA, INC.
PURCHASE
2,856——32,472May 28, 2021Jun 2, 2021 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
1,307——1,307May 28, 2021Jun 2, 2021 ↗View →
NTRA
NATERA, INC.
SALE
2,856——0May 28, 2021Jun 2, 2021 ↗View →
VERA
VERA THERAPEUTICS, INC.
SALE
2,187,504——0May 18, 2021May 18, 2021 ↗View →
VERA
VERA THERAPEUTICS, INC.
PURCHASE
727,272$11.00$8.00M2,914,776May 18, 2021May 18, 2021 ↗View →
VERA
VERA THERAPEUTICS, INC.
PURCHASE
2,187,504——2,187,504May 18, 2021May 18, 2021 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASE
1,104,209——1,104,209Feb 9, 2021Feb 9, 2021 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASE
450,000$20.00$9.00M2,754,437Feb 9, 2021Feb 9, 2021 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
1,104,209——0Feb 9, 2021Feb 9, 2021 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
SALE
1,200,228——0Feb 9, 2021Feb 9, 2021 ↗View →
BOLT
BOLT BIOTHERAPEUTICS, INC.
PURCHASE
1,200,228——2,304,437Feb 9, 2021Feb 9, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jan 11, 2021Jan 13, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
950,000——0Sep 29, 2020Oct 1, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
213,546——434,555Sep 29, 2020Oct 1, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
983,221——950,000Aug 28, 2020Sep 1, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
221,009——221,009Aug 28, 2020Sep 1, 2020 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
2,856——2,856Jun 12, 2020Jun 16, 2020 ↗View →
NTRA
NATERA, INC.
PURCHASEGRANT
Stock grant
5,712——5,712Jun 12, 2020Jun 16, 2020 ↗View →
ITRM
ITERUM THERAPEUTICS PLC
SALE
400,000$1.61$643.0K1,226,514Jun 2, 2020Jun 3, 2020 ↗View →
ITRM
ITERUM THERAPEUTICS PLC
SALE
100,000$1.69$169.1K1,626,514Jun 1, 2020Jun 3, 2020 ↗View →
ITRM
ITERUM THERAPEUTICS PLC
PURCHASEGRANT
Stock grant
—$1,750,000.00——Jan 21, 2020Jan 21, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
20,000——0Jan 12, 2020Jan 13, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
20,000$12.37$247.4K70,086Jan 12, 2020Jan 13, 2020 ↗View →
NTRA
NATERA, INC.
SALE
11,169——0Jan 10, 2020Jan 14, 2020 ↗View →
NTRA
NATERA, INC.
PURCHASE
11,169$10.41$116.3K29,616Jan 10, 2020Jan 14, 2020 ↗View →
NTRA
NATERA, INC.
PURCHASE
11,169$11.80$131.8K18,447Jan 10, 2020Jan 14, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jan 10, 2020Jan 14, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
29,994——0Jan 9, 2020Jan 13, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
20,000——0Jan 9, 2020Jan 13, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
20,000$10.05$201.0K50,086Jan 9, 2020Jan 13, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
29,994$1.67$50.0K30,086Jan 9, 2020Jan 13, 2020 ↗View →
Other insiders · BIOA
Loading peer insiders…
About this filer
CIK 0001245624
ROLE
Director
PRIMARY
BIOA
COMPANIES
8
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001245624DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback